Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 360

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 360
---
 ongoing reduction in genetic sequencing and data processing costs, which have decreased substantially in recent years and continue to trend downward. This decline has been driven by advancements in sequencing technology and bioinformatics, therefore making genetic testing more affordable and accessible to a broader population. According to industry public reports titled “DNA Sequencing Costs: Data”, published by National Human Genome Research Institute on May16, 2023, and “Cost of NGS”, published by Illumina in April 2023, the sequencing cost -per-genomehas decreased approximately 96% over the past ten years. We believe this downward trend increases the potential reach and penetration of our services in sizeable and underserved populations in a range of geographies. In addition, we expect that our business -to-business-to-consumerproduct distribution model will deliver greater market penetration at a lower cost when compared to our previous direct -to-consumermodel. • Sustainable and inclusive growth: we are committed to working with all of our strategic partners to ensure that genetic testing is continuously improved. This is critical in the context of growing demand and mass adoption of these technologies. Likewise, we will focus on making our products increasingly affordable and broadly available. History and Development OmnigenicsAI was created as an artificial intelligence -drivengenomics company that grows through strategic partnerships, acquisitions, and exclusive licenses with the mission of providing secure, precise, and reliable biological data that enables people to live healthier lives. OmnigenicsAI incorporated the intellectual property rights, including trade secrets, of Heritas Argentina, a precision medicine company from Argentina focused on the Latin American market and plans to develop our strategic consortium. Heritas Argentina has been a genomics pioneer in Latin America for over eight years with proprietary developed tests and prevention services, primarily distributed through partnerships. By combining the strengths of our current and future partnerships, we expect to position ourselves as a leading AI -enabledgenomics company. OmnigenicsAI’s expertise spans biological, scientific, technological and market know -how, all of which are critical for product development and execution. Supported by a diverse and specialized team, we are crafting a highly complementary and comprehensive product portfolio that addresses a broad spectrum of health needs. 178 We believe we are pioneering the integration of genomic testing results with clinical and lifestyle data in the region. This combination creates enriched genomic datasets filled with potential insights, which we expect to be disruptive of patient’s healthcare, specially, since there are no data sets built from Latin American genes, a population not only present in the region, but is growing globally as